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A B S T R A C T
Background
Ginkgo is used in the treatment of peripheral vascular disease and ’cerebral insufficiency’. It is thought to have several potential
mechanisms of action including increased blood flow, platelet activating factor antagonism, and prevention of membrane damage
caused by free radicals. Vascular factors and oxidative damage are thought to be two potential mechanisms in the pathology of age-
related macular degeneration (AMD).
Objectives
The objective of this review was to determine the effect of Ginkgo biloba extract on the progression of AMD.
Search methods
We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2012, Issue
10), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMED-
LINE (January 1946 to October 2012), EMBASE (January 1980 to October 2012), Allied and Complementary Medicine Database
(AMED) (January 1985 to October 2012), OpenGrey (System for Information on Grey Literature in Europe) (www.opengrey.eu/),
the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO
International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restric-
tions in the electronic searches for trials. We last searched the electronic databases on 5 October 2012. We searched the reference lists
of identified reports and the Science Citation Index. We also contacted investigators of included studies for additional information.
Selection criteria
All randomised trials in people with AMD where Ginkgo biloba extract had been compared to control were included.
Data collection and analysis
The review author extracted data using a standardised form. The data were verified with the trial investigators. Trial quality was assessed.
Main results
Two published trials were identified that randomised a total of 119 people. In one study conducted in France, 20 people were randomly
allocated to Gingko biloba extract EGb 761 80 mg twice daily or placebo. In the other study conducted in Germany, 99 people were
randomly allocated to two different doses of Ginkgo biloba extract EGb 761 (240 mg per day and 60 mg per day). Treatment duration
in both studies was six months. Both trials reported some positive effects of Ginkgo biloba on vision however their results could not be
pooled. Adverse effects and quality of life for people with AMD were not reported.
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Authors’ conclusions
The question as to whether people with AMD should take Ginkgo biloba extract to prevent progression of the disease has not been
answered by research to date. Two small trials have suggested possible benefit of Gingko biloba on vision and further trials are warranted.
Ginkgo biloba is widely used in China, Germany, and France. Future trials should be larger, and last longer, in order to provide a more
robust measure of the effect of Gingko biloba extract on AMD.
P L A I N L A N G U A G E S U M M A R Y
Use of Gingko biloba, an extract from the leaves of the maidenhair tree, for slowing the progression of age-related macular
degeneration
Age-related macular degeneration (AMD) is a condition affecting the central area of the retina (the back of the eye). The retina can
deteriorate with age and some people get lesions that lead to loss of central vision. Gingko biloba, extracted from the leaves of the
maidenhair tree, is used in Chinese herbal medicine to treat a variety of medical conditions, in particular circulatory problems. Ginkgo
biloba extract contains two constituents (flavonoids and terpenoids) which have antioxidant properties. It is believed these may help to
slow down the progression of AMD. The author identified two small randomised controlled studies (with a total of 119 participants);
one in France and one in Germany. One trial compared Gingko biloba to placebo and the other compared two different doses of the
extract. Although both trials reported some positive effects of Ginkgo biloba on vision, the trials were small and of short duration.
Adverse effects and quality of life were not assessed. The overall conclusion of this review is that current research has not answered the
question as to whether Ginkgo biloba is of benefit to people with AMD. Future trials need to include a larger number of participants
and be conducted over a longer time.
B A C K G R O U N D
Description of the condition
Age-related macular degeneration is a disease affecting the central
area of the retina (the macula). In the early stages of the disease,
lipid material accumulates in deposits underneath the retinal pig-
ment epithelium. These deposits are known as drusen and can be
seen as pale yellow spots on the retina. The pigment of the retinal
epithelium may become disturbed with areas of hyperpigmenta-
tion and hypopigmentation. In the later stages of the disease, the
retinal pigment epitheliummay atrophy completely. This loss can
occur in small focal areas or it can be widespread (geographic). In
some cases, new blood vessels grow under the retinal pigment ep-
ithelium and occasionally into the subretinal space (exudative or
neovascular AMD). Haemorrhage can occur, which often results
in increased scarring of the retina.
The early stages of the disease are in general asymptomatic. In
the later stages there may be considerable distortion of vision and
complete loss of visual function, particularly in the central area of
vision. Population-based studies suggest that, in people 75 years
and older, approximately 30% have early signs of the disease and
7% have late stage disease (Klein 1992). It is the most common
cause of blindness and visual impairment in industrialised coun-
tries. For example, in the UK over 30,000 people are registered as
blind or partially sighted annually, half of whom have lost their
vision due to macular degeneration (Evans 1996). Currently there
is no treatment which can restore vision in AMD.
Description of the intervention
The use of extracts from the leaves of Ginkgo biloba (maidenhair
tree) for medical purposes originated in China; the extracts are
commonly prescribed in Germany and France (Kleijnen 1992).
There are two main extracts that have similar constituents: EGb
761, which consists of 24% ginkgo-flavone glycosides and 6%
terpenoids; and LI1370, which has 25%ginkgo-flavone glycosides
and 6% terpenoids.
How the intervention might work
Ginkgo is used in the treatment of peripheral vascular disease
and ’cerebral insufficiency’. It is thought to have several potential
mechanisms of action:
1. increased blood flow;
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2. platelet activating factor antagonism;
3. prevention of membrane damage caused by free radicals.
Vascular factors and oxidative damage are thought to be two po-
tential mechanisms in the pathology of AMD. Animal studies sug-
gest that EGb 761 protects mammalian retinal cells from damage
(Droy-Lefaix 1993; Droy-Lefaix 1995; Pritz-Hohmeier 1994).
Why it is important to do this review
Complementary therapies such as Ginkgo biloba can be widely
adopted without adequate evidence of potential benefits and
harms. It is important to have a systematic assessment of the evi-
dence for use of Ginkgo biloba for AMD, to inform patients and
clinicians.
O B J E C T I V E S
The objective of this review was to assess the effect of Ginkgo
biloba extract on the progression of AMD and to evaluate any
potential harmful effects.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Only randomised controlled trials were eligible for inclusion in
this review.
Types of participants
Participants in the trials were people with AMD in one or both
eyes.
Types of interventions
Trials in which the intervention was Ginkgo biloba, compared to
placebo or no intervention, were included. Two main extracts of
Ginkgo were considered: EGb 761 and LI1370.
Types of outcome measures
The following outcomes were used:
1. number of participants with disease progression;
2. number of participants with new visual loss due to AMD;
3. quality of life measures;
4. any adverse outcomes reported.
The definitions used were as follows.
AMD: this was taken as defined by trial investigators. It is com-
monly defined as: in the macular area 3000 microns diameter
from fovea, drusen with or without pigmentary abnormalities or
geographic atrophy or characteristic choroidal neovascularisation
with no other cause.
Progressionof disease: development of drusen, geographic atrophy,
or growth or progression of new vessels in the retina.
Visual loss: any well-defined outcome based on visual acuity was
used, depending on the way in which authors presented trial data.
Quality of life: any validated measurement scale which aims to
measure the impact of visual function loss on quality of life of
participants.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) 2012, Issue 10, part of The Cochrane Library.
www.thecochranelibrary.com (accessed 5 October 2012), Ovid
MEDLINE, Ovid MEDLINE In-Process and Other Non-In-
dexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE
(January 1946 to October 2012), EMBASE (January 1980 to
October 2012), Allied and Complementary Medicine Database
(AMED) (January 1985 toOctober 2012), OpenGrey (System for
Information on Grey Literature in Europe) (www.opengrey.eu/),
the metaRegister of Controlled Trials (mRCT) (www.controlled-
trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the
WHO International Clinical Trials Registry Platform (ICTRP) (
www.who.int/ictrp/search/en). We did not use any date or lan-
guage restrictions in the electronic searches for trials. We last
searched the electronic databases on 5 October 2012.
The UK Clinical Trials Gateway is no longer being searched for
this review as the other trials websites which are being searched
are more comprehensive.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1), MEDLINE (Appendix 2), EMBASE (Appendix
3), OpenGrey (Appendix 4), AMED (Appendix 5), mRCT
(Appendix 6), ClinicalTrials.gov (Appendix 7) and the ICTRP
(Appendix 8).
We reviewed all the possible trials identified that included aGinkgo
biloba intervention to see if participants with macular degenera-
tion were specifically included.
Searching other resources
We searched the reference lists of identified trial reports to find
additional trials. We used the Science Citation Index to find stud-
ies which had cited the identified trials. Investigators were con-
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tacted to identify additional published and unpublished studies.
We searched the database of randomised controlled trials compiled
by the Cochrane Complementary Medicine Field in the initial
search for the review.
Data collection and analysis
Selection of studies
The author reviewed the titles and abstracts of all reports of trials
identified by the electronic searching. The full text hard copies of
possible trials of the effect of Ginkgo biloba on AMD were ob-
tained. Relevant studies were selected according to the definitions
in the ’Criteria for considering studies for this review’.
Data extraction and management
The author extracted data using a standardised form developed
by the Cochrane Eyes and Vision Group. These data were verified
with the trial investigators.
Assessment of risk of bias in included studies
This was a new feature for the update in 2009. Assessment of the
risk of bias was done using the Cochrane Collaboration’s tool for
assessing the risk of bias as described in Chapter 8 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
The extent towhich bias could have been introduced in the follow-
ing aspects of study design and execution was assessed: sequence
generation, allocation concealment, blinding (masking), incom-
plete outcome data, and selective outcome reporting.
Measures of treatment effect
The risk ratiowas used for dichotomous outcomemeasures (for ex-
ample, ratio of clinical improvement to no clinical improvement).
The mean difference was used for continuous outcome measures,
such as visual acuity.
Unit of analysis issues
Ginkgo biloba extract is applied to the person but information on
two eyes can be reported. There are a variety of ways of dealing
with this but in both included studies the investigators reported
results for the worst affected eye only.
Assessment of reporting biases
Currently, with only two trials identified, it is not possible to assess
the role of publication bias.
Data synthesis
No summarymeasure was calculated because the two trials consid-
ered different comparisons (EGb 761: 160 mg/day versus placebo;
and EGb 761: 240 mg/day versus 60 mg/day) and reported data
in different formats.
R E S U L T S
Description of studies
See: Characteristics of included studies.
Results of the search
The electronic searches identified 616 titles and abstracts. We
screened the titles and abstracts according to the criteria outlined
above and found one trial of AMD (Lebuisson 1986). A further
trial was identified (Fies 2002) by one of the peer reviewers of this
review. The original searches were performed in December 1998
and the searches were updated in: February and September 2000,
December 2001, January 2006, and December 2008. No new tri-
als were found in the updated searches.
An update search was done in October 2012 which yielded eight
new records. The Trials Search Co-ordinator scanned the search
results and removed three references which were not relevant to
the scope of the review. The review author screened the title and
abstracts of the remaining five references and rejected them as not
eligible for inclusion in the review.
Included studies
Details can be found in the ’Characteristics of included studies’
table.
Types of participants
In the Lebuisson 1986 trial participants were people aged over 55
years. The participants were outpatients attending an eye clinic.
Similarly in the study by Fies 2002 participants were outpatient
attendees aged 59 years and above (average age approximately 75
years).
Types of intervention
Lebuisson 1986 compared 80 mg twice daily (160 mg) Ginkgo
biloba extract EGb 761 with a placebo which the authors stated
had the same appearance, smell, and taste. Treatment lasted six
months. Fies 2002 compared 240 mg EGb 761 daily with 60 mg
daily. Treatment and follow up lasted 24 weeks.
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Types of outcome measures
Outcomemeasures included: distance andnear visual acuity; visual
field; and clinical assessment of progression of disease. These were
measured at the end of the six-month treatment period.
Risk of bias in included studies
See Figure 1 and Figure 2.
Figure 1. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
5Ginkgo biloba extract for age-related macular degeneration (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
Allocation
Lebuisson 1986 was randomised appropriately by use of random
number tables. Whether or not the allocation was properly con-
cealed was not reported, however, the fact that the study was
placebo-controlled and the placebo was reported to be similar to
the active treatment suggests that the allocation was likely to be
concealed.
In Fies 2002 a randomisation list was prepared by a validated
EDP-random number generator. The numbers one to 100 were
allocated randomly to the treatment groups before the start of the
study. Participants received this number in consecutive order of
inclusion.
Blinding
In Lebuisson 1986 the assessment of outcome was not masked.
The placebo was prepared to have the same appearance, smell, and
taste; however, Ginkgo biloba has a characteristic bitter taste that
is difficult to mask (Knipschild 1998).
In Fies 2002 the investigators and participants weremasked during
the study.
Incomplete outcome data
In Lebuisson 1986 20 participants were followed up for sixmonths
but it was not clear if more participants were recruited initially. In
Fies 2002 there were dropouts reported but it was not clear exactly
how these were dealt with; the report suggested that an intention-
to-treat analysis was done.
Selective reporting
No suggestion of selective reporting as key outcomes, visual acuity
and clinical progression, were reported in both studies.
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Effects of interventions
Lebuisson 1986: 10 people were included in each treatment group.
Acuity (measured using a Snellen chart) improved in both groups
during the six months of treatment but to a greater extent in the
Ginkgo treated group. In the treatment group, average initial visual
acuity was 3.8/10 (standard deviation (SD) 0.6/10). At the end of
six months the average acuity was 6.1/10 (SD 0.8/10), an average
improvement in vision of 2.3/10 (SD 0.7/10). In the placebo
group, average initial visual acuity was 4.8/10 (SD 0.9/10). At the
end of six months the average acuity was 5.4/10 (SD 1.06/10), an
average improvement in vision of 0.6/10 (SD 0.7/10). This gives
a mean difference of 1.7/10 (95% confidence interval (CI) 0.12
to 0.22).
Tests of association for near vision and visual field were stated to
be not statistically significant. Clinical observation suggested that
nine out of 10 people in the treatment group improved compared
to two in the control group (risk ratio (RR) 4.5, 95% CI 1.28 to
15.81).
Fies 2002: 50 people were allocated to 240 mg/day and 49 people
to 60 mg/day. Both groups improved in terms of visual acuity
over the treatment period. There was no statistically significant
difference in average visual acuity at the end of the study (mean
difference in acuity at end of study 0.05, 95% CI -0.30 to 0.13).
Greater numbers of the high dose group improved by 0.2 or more
although this difference was not statistically significant (RR 1.85,
95% CI 0.91 to 3.75).
Adverse effects
Fies 2002: one person in the high dose group reported a headache;
one person in the high dose group had blood in the stools; and
two people in the low dose group experienced abdominal pain.
D I S C U S S I O N
Summary of main results
Two trials were identified that investigated the effect of Ginkgo
biloba on AMD. Both trials reported some positive effects of
Ginkgo biloba on vision. However, in both studies the visual acu-
ity of participants improved in both treatment and control groups.
With only two relatively small trials reported, this review does
not provide good systematic assessment of any potentially harm-
ful effects of Gingko biloba. Adverse effects related to bleed-
ing, such as subdural haematoma and hyphaema, have been re-
ported (Rosenblatt 1997; Rowin 1996). There have been several
Cochrane reviews of Ginkgo biloba for other conditions which
include a greater number of trials and, therefore, provide better
evidence of any potential harms (Birks 2009; Hilton 2004; Zeng
2005). None of these reviews have identified serious major adverse
effects associated with using Ginkgo biloba.
Overall completeness and applicability of
evidence
The studies reported were too small and short in duration to an-
swer conclusively the question as to whether Ginkgo biloba is of
benefit to people with AMD.
Quality of the evidence
As Gingko biloba is a pharmaceutical treatment there is the poten-
tial to mask active treatment. However, Ginkgo biloba has a char-
acteristic bitter taste that is difficult to mask (Knipschild 1998).
This issue was not considered in the placebo-controlled trial. Out-
come assessors were not masked and the only clinical outcome
reported did not have a clear case definition.
Potential biases in the review process
Publication bias could not be assessed as only two published trials
were identified.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Current research has not answered the question as to whether
Ginkgo biloba is of benefit to people with age-related macular
degeneration.
Implications for research
Two small trials have suggested possible benefit of Gingko biloba
on vision and further trials are warranted. Ginkgo biloba is widely
used inChina,Germany, andFrance. Future trials should be larger,
and last longer, in order to provide a more robust measure of
the effect on AMD. Care needs to be taken to provide a placebo
control that has a similar bitter taste as the active ingredient.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Fies 2002
Methods Method of allocation: validated EDP-random number generator
Masking: described as a “double blind” study
Provider: yes
10 participants from group 1 (high dose) and 3 participants from group 2 (low dose)
withdrew from the study
Participants Country: Germany, clinic of one of the investigators
Number of participants randomised: 99
Age (years): Group 1: 74 (59 to 89), Group 2: 77 (61 to 86)
Sex: male/female 27/72
Inclusion criteria: senile dry macular degeneration
Exclusion criteria: severe co-morbidities, decompensated cardiac insufficiency; heart at-
tack in the previous 4 weeks, pregnancy, alcohol or other substance abuse
Interventions Two doses of Ginkgo biloba extract EGb 761 were compared: 240 mg per day versus 60
mg per day
Duration of treatment: 24 weeks
Outcomes Visual acuity; withdrawals; side-effects
Notes Author contacted for information about the allocation concealment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Not clearly described in the published re-
port but contact with the investigator pro-
vided information that the allocation se-
quence was generated using a “validated
EDP-random number generator”
Allocation concealment (selection bias) Low risk Two different doses were compared and the
study was described as “double-blinded”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Two different doses were compared and the
study was described as “double-blinded”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 10 patients from the high dose group
dropped out compared to 3 patients from
the low dose group however unclear how
these people were analysed
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Fies 2002 (Continued)
Selective reporting (reporting bias) Low risk Visual acuity reported, which is a key out-
come
Other bias Low risk
Lebuisson 1986





Losses to follow up: none
Participants Country: France, outpatients at the Hospital Foch
Number of participants randomised: 20
Age: over 55 years, average age of 65 years (treatment) and 68 years (control)
Sex: not stated
Inclusion criteria: macular degeneration diagnosed within last year confirmed by angiog-
raphy; visual acuity better than 1/10
Exclusion criteria: people with (1) other ophthalmic conditions such as diabetic retinopa-
thy, retinochoroiditis, glaucoma or maculopathy of other origin (congenital, infectious,
inflammatory or myopic); (2) people where the fundus could not be seen; (3) people
who were likely to undergo laser photocoagulation during the trial period
Interventions Gingko biloba extract EGb 761 80 mg twice daily. Placebo identical in appearance,
smell, and taste




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “After the verification of the selection cri-
teria the patients received a case num-
ber that conditioned the treatment batch
which theywere given. An equal division of
the patients in to the 2 groupswasmade be-
fore the beginning of the study with the aid
of a permutation table.“ Translated from
French publication
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Lebuisson 1986 (Continued)
Allocation concealment (selection bias) Low risk Allocation concealmentwas not specifically
reported however:
“For the therapeutic trial, the patients were
prescribed either a dose of Gingko biloba
extract or a placebo, both of the same ap-
pearance, same smell and same taste - 2ml
to be taken twice a day, ie. for the Gingko
bilboa extract 80mg morning and evening.
” Translated from French publication
Blinding (performance bias and detection
bias)
All outcomes
High risk “For the therapeutic trial, the patients were
prescribed either a dose of Gingko biloba
extract or a placebo, both of the same ap-
pearance, same smell and same taste - 2ml
to be taken twice a day, ie. for the Gingko
biloba extract 80mg morning and evening.
” Translated from French publication
No information was given as to the ex-
tent to which participants, their carers and
people assessing outcome knew or guessed
the treatment allocation. Information from
study author suggests that outcome assess-
ment was unmasked
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information was provided on recruit-
ment into the trial - data reported on 20
patients but not clear if more patients were
recruited and whether any patients did not
complete the trial
Selective reporting (reporting bias) Low risk It was not clear from the report what the
primary outcome was. Only statistically
significant data on distance visual acuity
reported in the tables. Text suggests other
measures of visual function were not signif-
icantly different between groups. Subjec-
tive assessment of clinical improvement re-
ported. However, as visual acuity and clini-
cal progression are the key outcomes of this
review, for the purposes of this review selec-
tive reporting is not likely to be a problem
Other bias Low risk
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Macular Degeneration] explode all trees
#2 MeSH descriptor: [Retinal Degeneration] explode all trees
#3 MeSH descriptor: [Retinal Neovascularization] explode all trees
#4 MeSH descriptor: [Choroidal Neovascularization] explode all trees
#5 MeSH descriptor: [Macula Lutea] explode all trees
#6 macula* near lutea*
#7 (macula* or retina* or choroid*) near/4 degenerat*
#8 (macula* or retina* or choroid*) near/4 neovascul*
#9 maculopath*
#10 AMD or ARMD or CNV
#11 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10
#12 MeSH descriptor: [Ginkgo biloba] explode all trees
#13 ginkgo* or gingko* or gingkco* or ginko* or gingho* or gincosan*
#14 bilobalid* or tebonin* or kaveri* or tanakan* or rokan* or li-1370
#15 #12 or #13 or #14
#16 #11 and #15
Appendix 2. MEDLINE (OvidSP) search strategy
1. randomized controlled trial.pt.









11. 9 not (9 and 10)
12. 8 not 11
13. exp macular degeneration/
14. exp retinal degeneration/
15. exp retinal neovascularization/
16. exp choroidal neovascularization/
17. exp macula lutea/
18. maculopath$.tw.
19. ((macul$ or retina$ or choroid$) adj3 degener$).tw.
20. ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.
21. (macula$ adj2 lutea).tw.
22. (AMD or ARMD or CNV).tw.
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23. or/13-22
24. exp ginkgo biloba/
25. (ginkgo$ or gingko$ or gingkco$ or ginko$ or gingho$ or gincosan$).tw.
26. (bilobalid$ or tebonin$ or kaveri$ or tanakan$ or rokan$ or li-1370 or tanakan$).tw.
27. or/24-26
28. 23 and 27
29. 12 and 28
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville et al (Glanville 2006).
Appendix 3. EMBASE (OvidSP) search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.




18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp retina macula degeneration/
34. exp retina degeneration/
35. exp retina neovascularization/
36. exp subretinal neovascularization/
37. maculopath$.tw.
38. ((macul$ or retina$ or choroid$) adj3 degener$).tw.
39. ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.
40. exp retina macula lutea/
41. (macula$ adj2 lutea$).tw.
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42. (AMD or ARMD or CNV).tw.
43. or/33-42
44. exp Ginkgo Biloba/
45. (ginkgo$ or gingko$ or gingkco$ or ginko$ or gingho$ or gincosan$).tw.
46. (bilobalid$ or tebonin$ or kaveri$ or tanakan$ or rokan$ or li-1370 or tanakan$).tw.
47. or/44-46
48. 43 and 47
49. 32 and 48
Appendix 4. OpenGrey search strategy
(ginkgo or gingko or gingkco or ginko or gingho or gincosan or bilobalid or tebonin or kaveri or tanakan or rokan or li-1370 or super-
ginko) and (age related macular degeneration)
Appendix 5. AMED search strategy
1. exp ginkgo biloba/
2. (ginkgo$ or gingko$ or gingkco or ginko$ or gingho or gincosan or bilobalid$ or tebonin$ or kaveri or tanakan$ or rokan or li 1370
or li-1370 or super-ginko$).tw.
3. or/1-2
4. exp eye disease/
5. maculopath$.tw.
6. ((macul$ or retina$ or choroid$) adj3 degenerat$).tw.
7. ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.
8. (AMD or ARMD or CNV).tw.
9. or/4-8
10. 3 and 9
Appendix 6. metaRegister of Controlled Trials search strategy
(macular degeneration) AND (ginkgo or gingko or gingkco or ginko or gingho or gincosan or bilobalid or tebonin or kaveri or tanakan
or rokan or li 1370 or li-1370 or super-ginko)
Appendix 7. ClinicalTrials.gov search strategy
(Macular Degeneration) AND (Ginkgo OR Gingko OR Gingkco OR Ginko OR Gingho OR Gincosan OR Bilobalid OR Tebonin
OR Kaveri OR Tanakan OR Rokan OR Li 1370 OR Li-1370 OR Super-Ginko)
Appendix 8. ICTRP search strategy
macular degeneration = Condition AND ginkgo or gingko or gingkco or ginko or gingho or gincosan or bilobalid or tebonin or kaveri
or tanakan or rokan or li 1370 or li-1370 or super-ginko = Intervention
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WH A T ’ S N E W
Last assessed as up-to-date: 5 October 2012.
Date Event Description
22 November 2012 New search has been performed Issue 1, 2013: Electronic searches were updated.
22 November 2012 New citation required but conclusions have not
changed
Issue 1, 2013: No new trials were identified for inclu-
sion in this update
H I S T O R Y
Review first published: Issue 3, 1999
Date Event Description
14 January 2009 New search has been performed Issue 2, 2009: updated search yielded no new trials. Risk
of bias tables have been completed for existing included
studies
28 August 2008 Amended Converted to new review format.
5 May 1999 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
The Cochrane Eyes and Vision Group editorial team prepared and executed the electronic searches.
D E C L A R A T I O N S O F I N T E R E S T
None known.
I N D E X T E R M S
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Medical Subject Headings (MeSH)
Ginkgo biloba [∗chemistry]; Macular Degeneration [∗drug therapy]; Phytotherapy [∗methods]; Plant Extracts [∗therapeutic use];
Randomized Controlled Trials as Topic
MeSH check words
Humans
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